A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis
Summary: This narrative review synthesizes DFU’s complex etiology, affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, neuropathy, hyperglycemia-induced immune defects, and biofilms. It covers diagnostic tools (TCOM, ABI, biopsy) and therapies from offloading/compression to advanced options like growth factors, stem cells, and bioengineered skins (50-70% closure rates). Microbial dysbiosis (e.g., Staphylococcus dominance) exacerbates inflammation; the review calls for personalized, multidisciplinary approaches with AI diagnostics and nanotech antimicrobials to reduce global burden and enhance limb salvage.
Key Highlights:
- Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection.
- Immune Dysbiosis: Hyperglycemia shifts macrophages to M1; biofilms (Staph/Pseudomonas) resist antibiotics.
- Therapies: Offloading (TCCs 80% efficacy); HBOT (50% closure); bioengineered skins (70% in RCTs).
- Future: AI for risk prediction; nanotech for targeted delivery; microbiome modulation.
- Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading.
Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins